Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
198 Cards in this Set
- Front
- Back
Cholinergic drugs act on receptors that are activated by
a) Norepinephrine b) Acetylcholine |
Acetylcholine
|
|
In the sympathetic nervous system AcH binds with _______________ receptors at the pre/post synaptic ganglion
|
Nicotinic
Pre-synaptic |
|
In the adrenal medulla AcH binds at the pre/post synaptic and the receptor is muscarinic/nicotinic
|
Pre-synaptic
Nicotinic |
|
The nicotinic receptor is an example of a(n)
a) ion channel b) g-protein linked c) steroid d) enzyme |
ion channel
|
|
In the parasympathetic nervous system (choose all that apply)
a) AcH binds to muscarinic receptors pre-synaptically b) AcH binds to muscarinic receptors post-synaptically c) Has AcH binding both pre-synaptically & post-synaptically d) AcH binds only at the post-synaptic nicotinic receptor |
AcH binds to muscarinic receptors post-synaptically
Has AcH binding both pre-synaptically & post-synaptically |
|
Cholinergic drugs that are indirect acting (choose all that apply)
a) bind & activate the receptor b) inhibit breakdown of AcH by cholinesterase c) are also called anticholinesterase drugs |
inhibit breakdown of AcH by cholinesterase
are also called anticholinesterase drugs |
|
Clinical uses for cholinergic agonists include (choose all that apply)
a) reversal of neuromuscular blockade b) management of dementia c) Management of myastenia gravis d) treatment of glaucoma |
a) reversal of neuromuscular blockade
b) management of dementia c) Management of myastenia gravis d) treatment of glaucoma |
|
Synthesis of acetylcholine is a
made possible by (choose all that apply) a) Ca voltage channels once the reach threshold b) A Na concentration gradient c) Choline Acetyltransferase which catalyzes the reaction of choline with Acetyl CoA d) a negative feedback process |
b) A Na concentration gradient
c) Choline Acetyltransferase which catalyzes the reaction of choline with Acetyl CoA d) a negative feedback process |
|
Release of AcH is facilitated by (choose any that apply)
a) action potential at Ca voltage gated channel b) Elevated intracellular Ca c) Elevated intracellular Na |
a) action potential at Ca voltage gated channel
b) Elevated intracellular Ca |
|
When M1 or M3 receptors are activated
a) increase IP3 DAG b) decrease IP3 DAG c) increase cAMP d) decrease cAMP |
increase IP3 DAG
|
|
Cholinergic drugs act on receptors that are activated by
a) Norepinephrine b) Acetylcholine |
Acetylcholine
|
|
In the sympathetic nervous system AcH binds with _______________ receptors at the pre/post synaptic ganglion
|
Nicotinic
Pre-synaptic |
|
In the adrenal medulla AcH binds at the pre/post synaptic and the receptor is muscarinic/nicotinic
|
Pre-synaptic
Nicotinic |
|
The nicotinic receptor is an example of a(n)
a) ion channel b) g-protein linked c) steroid d) enzyme |
ion channel
|
|
In the parasympathetic nervous system (choose all that apply)
a) AcH binds to muscarinic receptors pre-synaptically b) AcH binds to muscarinic receptors post-synaptically c) Has AcH binding both pre-synaptically & post-synaptically d) AcH binds only at the post-synaptic nicotinic receptor |
AcH binds to muscarinic receptors post-synaptically
Has AcH binding both pre-synaptically & post-synaptically |
|
Cholinergic drugs act on receptors that are activated by
a) Norepinephrine b) Acetylcholine |
Acetylcholine
|
|
In the sympathetic nervous system AcH binds with _______________ receptors at the pre/post synaptic ganglion
|
Nicotinic
Pre-synaptic |
|
In the adrenal medulla AcH binds at the pre/post synaptic and the receptor is muscarinic/nicotinic
|
Pre-synaptic
Nicotinic |
|
The nicotinic receptor is an example of a(n)
a) ion channel b) g-protein linked c) steroid d) enzyme |
ion channel
|
|
In the parasympathetic nervous system (choose all that apply)
a) AcH binds to muscarinic receptors pre-synaptically b) AcH binds to muscarinic receptors post-synaptically c) Has AcH binding both pre-synaptically & post-synaptically d) AcH binds only at the post-synaptic nicotinic receptor |
AcH binds to muscarinic receptors post-synaptically
Has AcH binding both pre-synaptically & post-synaptically |
|
M1 receptors are found
a) CNS b) bronchial/smooth c) skeletal muscle d) stomach |
CNS (nerves)
stomach (parietal cells) |
|
M2 receptors are found
a) Cardiac b) bronchial/smooth c) skeletal muscle d) bladder |
Cardiac
bronchial/smooth SPASM (MOSTLY) skeletal muscle |
|
M3 receptors are found
a) Cardiac b) smooth muscle c) skeletal muscle d) bladder |
smooth muscle
bladder (MOSTLY) |
|
Cholinergic agonists cause
a) decreased HR & BP b) bronchospasm c) midrasis d) miosis e) increased GI motility |
a) decreased HR & BP
b) bronchospasm d) miosis e) increased GI motility |
|
T/F Muscarinic agonists release Nitric Oxide in the presence of endothelium and cause Vasodilation
|
TRUE, Nitric Oxide is an endothelial relaxing factor which causes VASODILATION in presence of endothelium
|
|
T/F When Muscarinic agonists cause release of Nitric Oxide in absence of endothelium there is Vasoconstriction
|
TRUE! In absence of endothelium Nitric Oxide causes VASOCONSTRICTION!!
|
|
Carbechol
a) a muscarinic/nicotinic cholinergic b) used to treat glaucoma c) causes miosis d) used to treat urinary retention |
a) a muscarinic/nicotinic cholinergic
b) used to treat glaucoma c) causes miosis |
|
Bethanechol
a) a muscarinic cholinergic b) used to treat urinary/gi retention c) can cause bradycardia d) a beta blocker |
a) a muscarinic cholinergic
b) used to treat urinary/gi retention c) can cause bradycardia |
|
Of the following which drug is NOT hydrolyzed by acetylcholinesterase
a) Carbechol b) Bethanechol c) Pilocarpine d) Methacholine |
MethaCHOLINE
|
|
Pilocarpine
a) used to treat glaucoma b) can cause central cholinergic syndrome c) causes miosis d) crosses BBB |
a) used to treat glaucoma
b) can cause central cholinergic syndrome c) causes miosis d) crosses BBB (tertiary amine) |
|
Physostigmine
a) reversibly binds to AcHase b) used to treat Central Anticholinergic Syndrome c) Can treat delirium d) is a irreversible bond at both muscarinic & nicotinic receptors |
a) reversibly binds to AcHase
b) used to treat Central Anticholinergic Syndrome c) Can treat delirium |
|
Neostigmine
a) a quartenary ammonium b) higher affinity for nicotinic than muscarinic receptor c) causes tachycardia d) causes bradycardia |
quartenary ammonium
higher affinity for nicotinic than muscarinic receptor causes bradycardia |
|
Edrophonium
a) used to diagnose Myasthenia Gravis b) used to treat Myasthenia Gravis c) short acting d) long acting |
used to diagnose Myasthenia Gravis
(because it is short acting) short acting ( 10-20 minutes) |
|
Pyridostigmine
a) used to diagnose Myasthenia Gravis b) used to treat Myasthenia Gravis c) short acting d) long acting |
used to treat Myasthenia Gravis (because it is long acting)
long acting ( 3-6 hours) |
|
Alzheimer's Disease
a) a deficit of cholinergic neurons b) an over abundance of cholinergic neurons c) treated with Donezepril d) treated with Rivastigmine |
a) a deficit of cholinergic neurons
c) treated with Donezepril d) treated with Rivastigmine |
|
Irreversible cholinergic inhibitors
a) organophospates b) echothiopate c) prevent breakdown of AcH d) can be reversed with Atropine |
a) organophospates
b) echothiopate c) prevent breakdown of AcH d) can be reversed with Atropine |
|
T/F Bethanechol, Carbachol & Pilocarpine bind preferentially at muscarinic receptors
|
TRUE
|
|
T/F pilocarpine & Physostigmine are uncharged tertiary amines that can penetrate CNS
|
TRUE
|
|
Which of the following has the longest duration of action
a) neostigmine b) physostigmine c) echothiopate d) Carbachol |
echothiopate
|
|
Other names for cholinergic antagonists include
a) cholinergic blockers b) anticholinesterase drugs c) anticholinergic drugs d) parasympatholitics |
cholinergic blockers
anticholinergic drugs parasympatholitics |
|
Atropine, Scopolamine, & Ipratroium are all
a) nicotinic blockers b) muscarinic blockers c) ganglionic blockers |
muscarinic blockers
|
|
Atropine
a) causes midrasis b) miosis c) bradycardia d) increases salivation |
causes midrasis
|
|
Which of the following drugs crosses the CNS
a) Atropine b) Scopolamine c) Glycopyrrolate |
a) Atropine
b) Scopolamine |
|
Anticholinergics side effects include
a) urinary retention b) constipation c) dry mouth d) thin secretions |
a) urinary retention
b) constipation c) dry mouth |
|
Which of the following has the most antisialagogue effect
a) atropine b) glycopyrrolate c) Scopolamine |
Scopolamine
|
|
Which of the following causes the most sedation
a) atropine b) glycopyrrolate c) Scopolamine |
Scopolamine
|
|
When treating urinary retention disorders you want a drug that has an affinity for which receptor
a) M1 b) M2 c) M3 d) M4 |
M3
|
|
Non-depolarizing muscle relaxants
a) competitively bind at nicotinic receptors b) competitively bind at muscarinic receptors c) can be overcome by increasing AcH at receptor site |
competitively bind at nicotinic receptors
can be overcome by increasing AcH at receptor site |
|
Examples of ganglionic blocking drugs
a) Buproprion b) chantax c) Oxytrol d) Detrol |
Buproprion
Chantax |
|
T/F Ganlionic blocking drugs are nonspecific blockers of both parasympathetic and sympathetic ganglia
|
TRUE
|
|
Adrenergic agonists
a) sympathomimetic drugs b) bind to alpha receptors c) bind to beta receptors |
a) sympathomimetic drugs
b) bind to alpha receptors c) bind to beta receptors |
|
The neurotransmitter found at adrenergic receptors
a) AcH b) NE c) Epi |
NE
Epi |
|
The second messenger associated with Beta adrenergic receptors
a) adenlyl-cyclase b) phospholipase-C c) guanlyl-cyclase |
adenlyl-cyclase
|
|
The second messenger associated with Alpha 1 adrenergic receptors
a) adenlyl-cyclase b) phospholipase-C c) guanlyl-cyclase |
phospholipase-C
|
|
Alpha 1 receptors
a) found on vascular smooth muscle b) cause vasodilation c) cause vasoconstriction d) found post-synaptically e) found pre-synaptically |
found on vascular smooth muscle
cause vasoconstriction found post-synaptically |
|
Activation of Alpha 1 receptors
a) decreases production of cAMP b) inhibits release of norepinephrine from neuron c) increase production of DAG & IP3 d) causes an increase in intracellular calcium e) found on post synaptic membrane of effector organ |
a) decreases production of cAMP
c) increase production of DAG & IP3 d) causes an increase in intracellular calcium e) found on post synaptic membrane of effector organ END RESULT CONSTRICTION OF SMOOTH MUSCLE |
|
Alpha receptors
a) more responsive to epinephrine b) more responsive to isuprel |
more responsive to epinephrine
>norepinephrine>isuprel |
|
Dopamine receptors
a) found in peripheral mesenteric vascular beds b) found in renal vascular beds c) found in CNS d) all of the above |
a) found in peripheral mesenteric vascular beds
b) found in renal vascular beds c) found in CNS |
|
T/F Alpha 2 receptors use feedback inhibition and decrease adenyl-cyclase activity
|
TRUE
|
|
Activation of the dopaminergic receptor
a) causes vasodilation b) causes vasoconstriction c) increases GFR d) decreases GFR |
causes vasodilation
increases GFR |
|
T/F Dopamine receptors are found in CNS effecting movement, affect, and nausea centers
|
TRUE
|
|
The precursor to endogenous catecholamines is ________________
|
Tyrosine
DOPA Dopamine Norepi |
|
T/F Alpha 2 receptor drugs can cause sedating effects
|
True, such as clonidine, because of the release of opiods
|
|
Beta 1 receptors ( choose all that apply)
a) cause tachycardia b) vasodilation c) increased renin release d) bronchodilation e) increased myocardial contractility |
cause tachycardia
increased renin release increased myocardial contractility |
|
Beta 2 receptors (choose all that apply)
a) cause vasodilation b) bronchodilation c) vasodilate vasculature in skeletal muscles d) decrease K, Ca, Mg, increase glucose r/t glycogen metabolism e) relaxed uterine smooth muscle |
cause vasodilation
bronchodilation vasodilate vasculature in skeletal muscles relaxed uterine smooth muscle decrease K, Ca, Mg, increase glucose r/t glycogen metabolism |
|
T/F Beta arrestin turns g-protein coupled receptors off to decrease # of receptors
|
True, causes the receptor to migrate to pits in cell membrane to be recycled
|
|
D1 receptors (choose all that apply)
a) renal dilators b) splanchnic dilators c) modulate CNS |
renal dilators
splanchnic dilators |
|
D2 receptors
a) renal dilator b) splanchnic dilator c) modulate neurotransmitters in CNS |
modulate neurotransmitters in CNS
|
|
Prolonged exposure to catechols
a) decreases number (downregulated) b) increases number (upregulated) |
decreases number (downregulated)
|
|
Lack of exposure to catechols
a) decreases number (downregulated) b) increases number (upregulated) |
increases number (upregulated)
|
|
The fundamental underlying mechanism for increasing contractility is
a) an increase in intracellular Calcium influx b) an increase in Na moving out of cell through slow Na channels |
an increase in intracellular Calcium influx
|
|
Beta 1 stimulation increases/decreases renin production
|
increases
|
|
Alpha 2 stimulation
increases/decreases renin production |
decreases
|
|
Which receptor causes an increase in platelet aggregation
a) Alpha 1 b) Alpha 2 c) Beta 1 d) Beta 2 |
Alpha 2 Epinephrine, this is a good drug for pt coming of coronary bypass pump
|
|
T/F Catecholamines are polar and do not readily penetrate the CNS
|
TRUE
|
|
Which of the following drugs are considered catecholamines
a) epinephrine b) isoproterenol c) ephedrine d) phenylephrine |
epinephrine
isoproterenol |
|
Direct acting adrenergic agonists
a) block uptake of norephinephrine b) cause the release of norephinephrine c) produce sympathetic effects |
produce sympathetic effects
|
|
Indirect acting adrenergic agonists
a) block uptake of norephinephrine b) cause the release of norephinephrine c) produce sympathetic effects |
cause the release of norephinephrine
|
|
T/F Catecholamines are polar and do not readily penetrate the CNS
|
TRUE
|
|
Which of the following drugs are considered catecholamines
a) epinephrine b) isoproterenol c) ephedrine d) phenylephrine |
epinephrine
isoproterenol |
|
Direct acting adrenergic agonists
a) block uptake of norephinephrine b) cause the release of norephinephrine c) produce sympathetic effects |
produce sympathetic effects
|
|
Indirect acting agonists
a) block uptake of norephinephrine b) cause the release of norephinephrine c) produce sympathetic effects |
cause the release of norephinephrine
|
|
Examples of direct acting adrenergic agonists are
a) Ephedrine b) Dobutamine c) Norepinephrine d) Cocaine e) Phenylephrine |
Dobutamine
Norepinephrine Phenylephrine |
|
Examples of indirect acting adrenergic agonists
a) Amphetamine b) Dobutamine c) Norepinephrine d) Cocaine e) Phenylephrine |
Amphetamine
Cocaine |
|
Which of the following is a mixed direct/indirect adrenergic agonist
a) Ephedrine b) Dobutamine c) Norepinephrine d) Cocaine e) Phenylephrine |
Ephedrine
|
|
What are the two types of cholinergic receptors?
|
nicotinic, muscarinic
|
|
Muscarinic receptors are found
a) pre-ganglionically in the PSNS neurons, but post-ganglionically in the SNS neurons b) post-ganglionically in the PSNS neurons, and not found in the SNS neurons c) post synaptically in the somatic neurons, and not found in the PSNS neurons |
post-ganglionically in the PSNS neurons, and not found in the SNS neurons
|
|
You have just given a cholinergic, muscarinic agonist
a) the sphincter of the iris will contract and cause miosis b) the sphincter of the iris will contract and cause mydriasis c) the sphincter of the iris will relax and cause miosis d) the sphincter of the iris will relax and cause mydriasis |
the sphincter of the iris will contract and cause miosis
|
|
T/F Cholinergic agonists will cause dilation of both arterial & venous dilation in low doses
|
True
|
|
M1 receptors are found
a) in the heart, smooth muscle b) in the lungs (bronchospasm) c) in the bladder, glands d) in the nerves, parietal cells |
in the nerves, parietal cells
|
|
M3 receptors are found
a) in the heart, smooth muscle b) in the lungs (bronchospasm) c) in the bladder, glands d) in the nerves, parietal cells |
in the bladder, glands
|
|
When an M1 receptor is stimulated what 2nd messenger(s) are activated and is there an increase or decrease in the 2nd
messenger a) ↑ IP3, DAG b) ↓ IP3, DAG c) ↓ cAMP d) ↑ cAMP |
↑ IP3, DAG
|
|
When an M2 receptor is stimulated what 2nd messenger(s) are activated and is there an increase or decrease in the 2nd
messenger a) ↑ IP3, DAG b) ↓ IP3, DAG c) ↓ cAMP d) ↑ cAMP |
↓ cAMP
|
|
. When an M3 receptor is stimulated what 2nd messenger(s) are activated and is there an increase or decrease in the 2nd
messenger a) ↑ IP3, DAG b) ↓ IP3, DAG c) ↓ cAMP d) ↑ cAMP |
↑ IP3, DAG
|
|
. The effect that cholinergic agonists has on the bladder & sphincter
a) contraction of detrusor muscle b) relaxation of detrusor muscle c) contraction of sphincter d) relaxation of sphincter |
contraction of detrusor muscle
relaxation of sphincter |
|
. T/F GI motility is increased with cholinergic agonists
|
True
|
|
Nicotinic receptors are ___________receptors
Muscarinic receptors are ___________ receptors |
ion channel
g-protein |
|
. Bethanechol, Carbachol, and Pilocarpine
a) direct acting cholinergic agonists b) indirect acting cholinergic agonists c) act on muscarinic receptors d) act on nicotinic receptors |
direct acting cholinergic agonists
act on muscarinic receptors |
|
Direct acting cholinergic drugs act by
a) increasing AcH by inhibiting hydrolysis of AcH b) decreasing AcH by increasing hydrolysis of AcH c) mimic effects of AcH by binding directly to the cholinergic receptor |
mimic effects of AcH by binding directly to the cholinergic receptor
|
|
. Bethanechol (choose all that apply)
a) structurally related to AcH b) hydrolyzed by acetylcholinesterase c) lacks nicotinic actions d) acts on the smooth musculature of bladder & gi tract |
structurally related to AcH
lacks nicotinic actions acts on the smooth musculature of bladder & gi tract |
|
. Indirect acting cholinergic drugs act by
a) increasing AcH by inhibiting hydrolysis of AcH b) decreasing AcH by increasing hydrolysis of AcH c) mimic effects of AcH by binding directly to the cholinergic receptor |
increasing AcH by inhibiting hydrolysis of AcH
|
|
. Physostigmine (choose all that apply)
a) direct acting cholinergic agonist b) indirect acting cholinergic agonist c) effects both muscarinic & nicotinic receptors d) enters the CNS |
indirect acting cholinergic agonist
effects both muscarinic & nicotinic receptors enters the CNS |
|
. Physostigmine used to treat (choose all that apply)
a) central cholinergic syndrome b) central anticholinergic syndrome c) atonic bladder or bowel d) glaucoma |
central anticholinergic syndrome
atonic bladder or bowel glaucoma |
|
T/F Physostigmine reversibly binds to acetylcholinesterase and inhibits its action
|
True
|
|
Which of the following drugs would be used to diagnose Myasthenia Gravis, and why?
a) Pyridostigmine b) Neostigmine c) Edrophonium |
Edrophonium, because it is short acting vs pyridostigmine and neostigmine
|
|
Alzheimer’s Disease increased/decreased cholinergic receptors in CNS
|
decreased
|
|
Which of the following drugs would be used to treat Alzheimer’s Disease (choose all that apply)
a) Donezepril b) Captopril c) Rivastigmine d) Glantamine |
Donezepril
Rivastigmine Glantamine |
|
How are irreversible cholinesterase inhibitors treated?
|
with atropine
|
|
Match the dose of Atropine with the expected effect
0.03mg ..............................↓gi/bladder 0.8 -1mg ............................ bradycardia 2-3mg .................................tachycardia, mydrasis, bronchodilation 4-5mg .................................dry mouth, ↓ bronchial secretions |
0.03 bradycardia
0.8-1mg tachycardia, mydriasis, bronchodilation 2-3mg dry mouth, ↓bronchial secretions 4-5mg ↓ gi/bladder |
|
. Adverse effects of cholinergic antagonists include (choose all that apply)
a) CNS toxicity b) constipation c) urinary retention d) bronchospasm |
CNS toxicity
constipation urinary retention |
|
Your pt is on an Epi drip at 1mcg/kg/min, you give 1mg of Propanolol and continue the drip you would expect
a) HR to decrease, contractility to decrease, BP to decrease b) HR to increase, contractility to decrease, BP to increase c) HR to decrease, contractility to decrease, BP to increase |
HR to decrease, contractility to decrease, BP to increase
|
|
Prior to giving Isuprel your pt was α-blocked what would the BP do? increase/decrease/stay the same
|
stay the same (because Isuprel is strictly a beta drug)
|
|
Prior to giving some Epi your pt was α-blocked what would the BP do? increase/decrease/stay the same
|
decrease
|
|
Prior to starting your pt on a levo drip he was α-blocked what would the BP do? increase/decrease/stay the same
|
decrease (levophed is both alpha and beta)
|
|
Clonidine (choose all that apply)
a) α1 agonist b) α2 agonist c) exerts its effect both peripherally & centrally d) inhibits sympathetic tone e) inhibits NE release |
α2 agonist
exerts its effect both peripherally & centrally inhibits sympathetic tone inhibits NE release |
|
Drugs used to treat bronchospasms
a) β2-blockers b) β2 agonists |
β2 agonists
|
|
Albuterol, Metaproterenol short acting/ medium acting/ long acting
|
medium acting
|
|
. What is the problem with using short acting/ medium acting adrenergics for bronchospasm?
|
(think receptors) using short acting causes up & down regulation of
receptors, and so are not effective in long term treatment |
|
Match the receptor type with its location in the body (may be more than one answer for some)
α1 ........................lungs β2........................ Smooth vascular α2 ........................ heart β3.......................CNS D1 ....................... Renal D2...................... adipose tissue β1...................... Nerve endings ...........................Splanchnic ...........................uterine |
Smooth vascular α1 β2
Lungs β2 Heart β1 CNS α2 Renal D1 vascular skeletal β2 Nerve endings D2 Splanchnic D1 Uterine β2 Adipose tissue β3 |
|
The 2nd messenger for α1 receptor
a) adenyl cyclase b) phospholipase C |
phospholipase C
|
|
α1 receptors
a) vasoconstriction b) vasodilation c) ↑ peripheral resistance d) mydriasis e) miosis |
vasoconstriction
↑ peripheral resistance mydriasis |
|
α2 receptors
a) inhibit NE release b) inhibit insulin release c) tachycardia d) sedation e) ↓ renin release |
inhibit NE release
inhibit insulin release sedation ↓ renin release |
|
β1 receptors
a) tachycardia b) vasodilation c) ↑ renin release d) metabolism changes ( ↑ glucose, ↓ K, Ca, Mg) |
tachycardia
↑ renin release |
|
β2 receptors
a) vasodilation b) bronchodilation c) increased muscle/liver glycogenolysis d) relax uterine muscle |
vasodilation
bronchodilation increased muscle/liver glycogenolysis relax uterine muscle |
|
What cholinergic antagonist is also a ganglionic blocker & is used to treat HTN
|
Trimethaphan
|
|
Aldomet (Methyldopa)
a) a dopaminergic drug b) α2 agonist c) converted to methylnorepinephrine & diminishes adrenergic outflow in the CNS d) ↓ peripheral resistance & ↓ BP |
α2 agonist
converted to methylnorepinephrine & diminishes adrenergic outflow in the CNS ↓ peripheral resistance & ↓ BP |
|
. Aldomet
a) ↓ CO b) does not ↓ CO c) good drug for renal pts d) side effects of sedation, drowsiness |
does not ↓ CO
good drug for renal pts side effects of sedation, drowsiness |
|
. Hydralazine
a) direct vasodilation b) indirect vasodilation c) causes reflex tachycardia d) ↑ renin release → Na & H2O retention e) used in combination with β-blockers (propanolol) |
direct vasodilation
causes reflex tachycardia ↑ renin release → Na & H2O retention used in combination with β-blockers (propanolol) |
|
T/F Hydralazine increases myocardial contractility, HR, and MVO2
|
True
|
|
α-blockers
a) arterial/venous dilation b) prevent HTN when exposed to catecholamines c) ↑ HR, renin, ADH d) reverse vasoconstriction caused by Epinephrine |
arterial/venous dilation
prevent HTN when exposed to catecholamines ↑ HR, renin, ADH reverse vasoconstriction caused by Epinephrine |
|
T/F Angiotensin Blockers will allow renin release, but not Na & H2O retention
|
True
|
|
Which Ca Channel blockers are more active in the heart vs vascular smooth muscle
a) Nifedipine b) Diltiazem c) Nicardipine d) Verapamil |
Diltiazem
Verapamil |
|
Which Ca Channel blockers are more active in the vascular smooth muscle vs heart
a) Nifedipine b) Diltiazem c) Nicardipine d) Verapamil |
Nifedipine
Nicardipine |
|
Your pt has SVT which Ca Channel blockers would you use
a) Nifedipine b) Diltiazem c) Nicardipine d) Verapamil |
Diltiazem
Verapamil |
|
ACE Inhibitors
a) ↓ SNS output b) ↓ aldosterone c) ↑ aldosterone d) ↑ bradykinin |
↓ SNS output
↓ aldosterone ↑ bradykinin |
|
Which Ca Channel blockers have some effect on coronary vasodilation
a) Diltiazem b) Nicardipine c) Nifedipine d) Verapamil |
Diltiazem
Nifedipine Verapamil |
|
T/F Dihydropyridines cause reflex sympathetic activation & edema
|
True
|
|
Nicardipine
a) has a ceiling effect b) can be rapidly titrated in HTN emergency c) can not be rapidly titrated d/t long ½ life d) good drug for Neuro-anesthesia (only minimal ↑ CBF) e) causes coronary vasodilation |
has a ceiling effect
can not be rapidly titrated d/t long ½ life good drug for Neuro-anesthesia (only minimal ↑ CBF) causes coronary vasodilation |
|
β-blockers ↓ BP by
a) ↓ stress related to HTN b) ↓ renin production c) ↑ aldosterone d) block β adrenoreceptors on heart |
↓ stress related to HTN
↓ renin production block β adrenoreceptors on heart |
|
The administration of Nitrates
a) ↑ cGMP b) ↓ cGMP c) ↑ Nitric Oxide d) ↑ dephosphorylation of light chain myosin e) ↓ dephosphorylation of light chain myosin |
↑ cGMP
↑ Nitric Oxide ↑ dephosphorylation of light chain myosin |
|
Molecule is made up of Fe, Cyanide (CN), Nitric Oxide
a) Nitroglycerin b) Nitroprusside |
Nitroprusside
|
|
You are administering a nitrate to your patient and notice a ↓ LOC and upon drawing some labs see that he is in metabolic acidosis. This drug is rapidly
metabolized by RBC’s the drug is a) Nitroprusside b) Nitroglycerin |
Nitroprusside
|
|
How is cyanide toxicity from Nitroprusside treated
a) Vit B 12 b) Thiosulfate |
Vit B 12
|
|
Systemic effects of Nitroprusside
a) ↑ cerebral blood flow b) inhibits platelet aggregation c) ↑ platelet aggregation d) blocks hypoxic pulmonary vasoconstriction reflex |
↑ cerebral blood flow
inhibits platelet aggregation blocks hypoxic pulmonary vasoconstriction reflex |
|
Vasodilators work by
a) ↑ LV afterload b) ↓ LV afterload c) venous decompression d) venous pooling e) improving RV function thru pulmonary vasodilation |
↓ LV afterload
venous decompression improving RV function thru pulmonary vasodilation |
|
How does Vit B12 work when used for cyanide poisoning?
|
displacing the drug from the receptor
|
|
Nitroprusside or Nitroglycerin which one dilates coronary’s and can be used for vasospasm in the uterus?
|
Nitroglycerin
|
|
T/F Nitroglycerin exerts it’s effect on smooth muscle relaxation by release of endothelial Nitric Oxide
|
True
|
|
Nitroglycerin
a) ↓ cGMP b) ↓ preload c) ↑ preload d) dilates lg coronary arteries e) ↓ LVEDP |
↓ preload
dilates lg coronary arteries ↓ LVEDP cGMP would increase because cGMP vasodilates |
|
Your pt has Torsades de Pointe what would you treat it with?
|
Mg or Phenytoin or propanolol or lidocaine
|
|
Trimethaphan
a) blocks SNS ganglia only b) blocks SNS & PSNS ganglia c) ↓ BP by ↓ preload (CO & SVR) d) reflex tachy e) binds to nicotinic receptors f) can be used to ↓ intraoperative bleeding |
blocks SNS & PSNS ganglia
↓ BP by ↓ preload (CO & SVR) binds to nicotinic receptors can be used to ↓ intraoperative bleeding |
|
What vasodilator causes lupus like syndrome (Steven-Johnson’s) and may be a problem in slow acetylators
a) Nitroprusside b) Hydralazine c) Fenoldopam d) Nicardipine |
Hydralazine
|
|
T/F Enalaprit (Vasotec) causes ↑ renin release and ↑ bradykinin
|
True
|
|
. Fenoldopam
a) α agonist b) D1 agonist c) renal artery dilation d) natiuretic |
D1 agonist
renal artery dilation natiuretic |
|
Brain Natiuretic Peptide, pulmonary vasodilator, used to treat CHF, Pulmonary Edema
a) Diazoxide b) Nesiritide c) Phentolamine d) Enalaprit |
Nesiritide
|
|
Side effects of vasodilators include
a) reflex tachy b) Na & H2O retention c) ↓ aldosterone d) HOTN |
reflex tachy
Na & H2O retention HOTN |
|
Which drug could be used to treat dig toxicity
a) Amiodorone b) Phenytoin c) Quinidine d) Flecinide |
Phenytoin
|
|
Nitric Oxide causes vasodilation in
a) all alveoli b) only ventilated alveoli |
only ventilated alveoli
|
|
Nitric Oxide
a) ↓ PA pressures b) endothelial-derived relaxing factor c) only approved in PPH (neonates) d) cause pulmonary edema |
↓ PA pressures
endothelial-derived relaxing factor only approved in PPH (neonates) cause pulmonary edema |
|
50% of people don’t respond to Nitric Oxide therapy but may if what drugs are added to the therapy?
|
Nitroprusside or Nitroglycerin
|
|
T/F Nitric Oxide inhalation therapy is beneficial in ARDS, RV failure after cardiac surgery & sickle cell crisis
|
True
|
|
Nitric Oxide is delivered in parts/million, if delivered at a rate 20 parts/million what could result?
|
Methemoglobinemia d/t free radicals
|
|
T/F Rebound Pulmonary HTN can occur after withdrawing Nitric Oxide therapy
|
True, need to withdraw slowly
|
|
Which of the following drugs produces CYP itself
a) Phenytoin b) Amiodorone c) Procainamide d) Quinidine |
Phenytoin
|
|
Which anti-dysrrhythmic drug could be a problem in pts who are slow acetylators
a) Phenytoin b) Amiodorone c) Procainamide d) Quinidine |
Procainamide
|
|
Which of the following anti-dysrrhythmic drugs are considered “membrane stabilizers”
a) Procainamide b) Propanolol c) Propafenone d) Lidocaine |
Procainamide
Propanolol Propafenone Lidocaine |
|
Which of the following drugs is both a class II & class III anti-dysrrhythmic drug
a) Amiodorone b) Sotolol d) Mexilitine e) Adenosine |
Sotolol
|
|
Class IA anti-dysrrhythmics
a) prolong the action potential b) have no effect on the action potential c) slows phase 0 depolarization d) suppresses phase 4 depolarization |
prolong the action potential
slows phase 0 depolarization |
|
Class IB anti-dysrrhythmics
a) decrease the duration of the action potential b) have no effect on the action potential c) shorten phase 3 repolarization d) prolong phase 3 repolarization |
decrease the duration of the action potential
shorten phase 3 repolarization |
|
Class IC anti-dysrrhythmics
a) decrease the duration of the action potential b) have no effect on the action potential c) slow phase 0 depolarization d) supress phase 4 depolarization |
have no effect on the action potential
slow phase 0 depolarization |
|
Class I drugs
a) Na channel blockers b) Ca channel blockers c) β-blockers d) K channel blockers |
Na channel blockers
|
|
Class II drugs
a) Na channel blockers b) Ca channel blockers c) β-blockers d) K channel blockers |
β-blockers
|
|
Class III drugs
a) Na channel blockers b) Ca channel blockers c) β-blockers d) K channel blockers |
K channel blockers
|
|
Class IV drugs
a) Na channel blockers b) Ca channel blockers c) β-blockers d) K channel blockers |
Ca channel blockers
|
|
Procainamide, Quinidine, Disopyramide all
a) Class IA drugs b) Class II drugs c) Class IB drugs d) Class IV drugs |
Class IA drugs
|
|
Lidocaine, Mexiletine
a) Class IA drugs b) Class II drugs c) Class IB drugs d) Class IV drugs |
Class IB drugs
|
|
Flecainide
a) Class IC drugs b) Class III drugs c) Class IB drugs d) Class IV drugs |
Class IC drugs
|
|
Esmolol, Propanolol, Sotolol
a) Class IA drugs b) Class II drugs c) Class IB drugs d) Class IV drugs |
Class II drugs
|
|
Amiodorone, Sotolol
a) Class III drugs b) Class II drugs c) Class IB drugs d) Class IV drugs |
Class III drugs
|
|
Diltiazem, Verapamil
a) Class IA drugs b) Class II drugs c) Class IB drugs d) Class IV drugs |
Class IV drugs
|
|
Which drug crosses all four anti-arrhythmic classes
a) Procainamide b) Amiodorone c) Disopyramide d) Sotolol |
Amiodorone
|
|
Propafenone, Procainamide, Amiodorone which drug has the following adverse effects
- Hyper &/or Hypo thyroidism - dig toxicity - blue skin coloring - inhibits CYP - pulmonary alveolitis |
Amiodorone
|
|
Increased levels of Flecainide can be seen when given in combination with (choose all that apply)
a) digoxin b) amiodorone c) propanolol d) Phenytoin |
digoxin
amiodorone propanolol |
|
Which of the following prostanoids are vasoconstrictors
a) TXA2 b) PGE1 c) PGE2 d) PGI2 e) PGF2α |
TXA2
PGE2 PGF2α |
|
Which of the following prostanoids are vasodilators
a) TXA2 b) PGE1 c) PGE2 d) PGI2 e) PGF2α |
PGE1
PGI2 |
|
Hemabate
a) PGF2α b) PGE1 c) used for post partum hemorrhage d) should not be used in a pt with asthma |
PGF2α
used for post partum hemorrhage should not be used in a pt with asthma |
|
Alprostadil
a) will close the PDA b) will keep the PDA open c) PGE1 d) PGE2 |
will keep the PDA open
PGE1 |
|
Epoprostanol (Flolan)
a) treat Pulm HTN b) PGI2 c) PGF2α d) requires continuous infusion d/t short ½ life |
treat Pulm HTN
PGI2 requires continuous infusion d/t short ½ life |
|
Iloprost
a) PGI2 b) PGI1 c) ↓ plt aggregation d) ↑ plt aggregation |
PGI2
↓ plt aggregation |
|
Thromboxane
a) PGI2 b) TXA2 c) ↑ plt aggregation d) ↓ plt aggregation |
TXA2
↑ plt aggregation |
|
Misoprostol (Cytotec)
a) PGE1 b) PGI2 c) ↑ gi motility d) proton pump inhibitor |
PGE1
↑ gi motility proton pump inhibitor |
|
Digoxin
a) increases Na+/K+ exchange b) decreases Na+/K+ exchange c) increases intracellular Ca++ d) decreases intracellular Ca++ |
decreases Na+/K+ exchange
increases intracellular Ca++ |
|
Digoixin
a) ↑ protein binding b) narrow therapeutic window c) ↑ duration of action potential d) ↓ duration of action potential e) ↑ PSNS activity on SA node f) increased conduction on rest of heart |
↑ protein binding
narrow therapeutic window ↓ duration of action potential ↑ PSNS activity on SA node (which slows heart rate) increased conduction on rest of heart |
|
Hypokalemia/Hyperkalemia causes dig toxicity
|
Hypokalemia
|
|
Hypercalcemia/Hypocalcemia causes dig toxicity
|
Hypercalcemia
|
|
Spironolactone
a) aldosterone antagonist b) K+ sparing c) loop diuretic d) aldosterone agonist |
aldosterone antagonist
K+ sparing |
|
Angiotensin Inhibitors
a) Captopril b) Losartan c) ↓ aldosterone d) ↓ angiotensin II e) ↑ bradykinin |
Losartan
↓ aldosterone ↓ angiotensin II ↑ bradykinin |
|
Bipyridines
a) Milrinone b) Eplerone c) phosphodiesterase inhibitors d) ↑cGMP e) ↑ cAMP |
Milrinone
phosphodiesterase inhibitors ↑cGMP (vasodilation) ↑ cAMP (contraction) |